A326030 Stock Overview
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A326030 from our risk checks.
SK Biopharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩83,300.00 |
| 52 Week High | ₩104,800.00 |
| 52 Week Low | ₩66,900.00 |
| Beta | 1.07 |
| 1 Month Change | -11.38% |
| 3 Month Change | -5.34% |
| 1 Year Change | 23.04% |
| 3 Year Change | -25.29% |
| 5 Year Change | n/a |
| Change since IPO | -34.41% |
Recent News & Updates
SK Biopharmaceuticals Co., Ltd. (KRX:326030) Not Lagging Industry On Growth Or Pricing
Apr 09
Is SK Biopharmaceuticals (KRX:326030) A Risky Investment?
Feb 27Shareholder Returns
| A326030 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -1.3% | 0.5% | -0.4% |
| 1Y | 23.0% | 7.1% | 4.5% |
Price Volatility
| A326030 volatility | |
|---|---|
| A326030 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | n/a | Dong Hoon Lee | www.skbp.com |
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It also develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder.
SK Biopharmaceuticals Co., Ltd. Fundamentals Summary
| A326030 fundamental statistics | |
|---|---|
| Market cap | ₩6.52t |
| Earnings (TTM) | -₩32.88b |
| Revenue (TTM) | ₩354.89b |
18.4x
P/S Ratio-198.4x
P/E RatioIs A326030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A326030 income statement (TTM) | |
|---|---|
| Revenue | ₩354.89b |
| Cost of Revenue | ₩34.08b |
| Gross Profit | ₩320.81b |
| Other Expenses | ₩353.69b |
| Earnings | -₩32.88b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -419.89 |
| Gross Margin | 90.40% |
| Net Profit Margin | -9.27% |
| Debt/Equity Ratio | 45.0% |
How did A326030 perform over the long term?
See historical performance and comparison